Latest news

Debiopharm and Aurigene sign licensing agreement for the development and commercialisation of Debio 0617, a novel inhibitor of an undisclosed…

Debiopharm and Pharmaleads sign license agreement for Debio 0827 or PL37 in treatment of chronic pain conditions

Debiopharm announces U.S. NDA filing of Trelstar® 6-month formulation for locally advanced or metastatic prostate cancer

Sanvar® (Debio 8609) for esophageal variceal bleeding – Debiopharm submits response to the FDA

Japanese Cancer Association and Debiopharm Honour Japanese Research – Professors Ichijo and Mano receive 2008 JCA-Mauvernay Award

Clinical Update – Debio 9902 SR (ZT-1) for Alzheimer Patients – Debiopharm Starts Tablet Formulation Bridging Study under IN

Debiopharm moves towards a new 6-month formulation of Decapeptyl® to further help prostate cancer patients

Debiopharm investit pour les médicaments innovants de demain – Inauguration de Campus “après-demain”, son site de développement et de production

Debiopharm and EPFL Sign Research Project Agreement to Identify Inhibitors of Signalling Pathways Controlling Cell Fate For Cancer Treatment